IL302745A - Compounds and their use in the treatment of tachykinin receptor mediated disorders - Google Patents
Compounds and their use in the treatment of tachykinin receptor mediated disordersInfo
- Publication number
- IL302745A IL302745A IL302745A IL30274523A IL302745A IL 302745 A IL302745 A IL 302745A IL 302745 A IL302745 A IL 302745A IL 30274523 A IL30274523 A IL 30274523A IL 302745 A IL302745 A IL 302745A
- Authority
- IL
- Israel
- Prior art keywords
- nk2r
- group
- agonist
- amino acids
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206509 | 2020-11-09 | ||
| PCT/EP2021/081057 WO2022096736A1 (en) | 2020-11-09 | 2021-11-09 | Compounds and their use in treatment of tachykinin receptor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302745A true IL302745A (en) | 2023-07-01 |
Family
ID=73198203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302745A IL302745A (en) | 2020-11-09 | 2021-11-09 | Compounds and their use in the treatment of tachykinin receptor mediated disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230406883A1 (enExample) |
| EP (1) | EP4240749A1 (enExample) |
| JP (1) | JP2023551122A (enExample) |
| KR (1) | KR20230106616A (enExample) |
| CN (1) | CN116745310A (enExample) |
| AU (1) | AU2021374843A1 (enExample) |
| CA (1) | CA3197916A1 (enExample) |
| CL (1) | CL2023001325A1 (enExample) |
| CO (1) | CO2023007404A2 (enExample) |
| IL (1) | IL302745A (enExample) |
| MX (1) | MX2023005408A (enExample) |
| PE (1) | PE20231952A1 (enExample) |
| WO (1) | WO2022096736A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023118263A1 (en) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonists for treatment of eating disorder |
| CN117384258B (zh) * | 2023-10-12 | 2024-07-26 | 湖南中晟全肽生物科技股份有限公司 | 一种神经激肽受体2（nk2r）激动剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660247A3 (en) * | 2009-05-08 | 2014-09-03 | Chongxi Yu | High penetration prodrug compositions of peptides and peptide-related compounds |
| CA2918245C (en) * | 2013-08-01 | 2022-08-30 | Dignify Therapeutics, Inc. | Compositions and methods for inducing urinary voiding and defecation |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| US11352391B2 (en) * | 2017-09-21 | 2022-06-07 | Dignify Therapeutics, Llc | Compositions for inducing urinary voiding and defecation |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| KR20220084035A (ko) * | 2019-10-17 | 2022-06-21 | 유니버시티 오브 코펜하겐 | Tacr2의 효능제 |
-
2021
- 2021-11-09 IL IL302745A patent/IL302745A/en unknown
- 2021-11-09 CN CN202180089751.3A patent/CN116745310A/zh active Pending
- 2021-11-09 WO PCT/EP2021/081057 patent/WO2022096736A1/en not_active Ceased
- 2021-11-09 PE PE2023001563A patent/PE20231952A1/es unknown
- 2021-11-09 CA CA3197916A patent/CA3197916A1/en active Pending
- 2021-11-09 JP JP2023528102A patent/JP2023551122A/ja not_active Ceased
- 2021-11-09 AU AU2021374843A patent/AU2021374843A1/en active Pending
- 2021-11-09 MX MX2023005408A patent/MX2023005408A/es unknown
- 2021-11-09 EP EP21802379.4A patent/EP4240749A1/en active Pending
- 2021-11-09 KR KR1020237016448A patent/KR20230106616A/ko active Pending
- 2021-11-09 US US18/252,056 patent/US20230406883A1/en active Pending
-
2023
- 2023-05-08 CL CL2023001325A patent/CL2023001325A1/es unknown
- 2023-06-05 CO CONC2023/0007404A patent/CO2023007404A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20231952A1 (es) | 2023-12-06 |
| WO2022096736A1 (en) | 2022-05-12 |
| US20230406883A1 (en) | 2023-12-21 |
| CA3197916A1 (en) | 2022-05-12 |
| CL2023001325A1 (es) | 2023-12-15 |
| MX2023005408A (es) | 2023-07-25 |
| AU2021374843A1 (en) | 2023-06-08 |
| KR20230106616A (ko) | 2023-07-13 |
| AU2021374843A9 (en) | 2024-08-08 |
| JP2023551122A (ja) | 2023-12-07 |
| CO2023007404A2 (es) | 2023-07-10 |
| EP4240749A1 (en) | 2023-09-13 |
| CN116745310A (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102351313B1 (ko) | Gip/glp1 공효능제 화합물 | |
| KR102444783B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| KR102440323B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| US20230406883A1 (en) | Compounds and their use in treatment of tachykinin receptor mediated disorders | |
| US12410227B2 (en) | Incretin analogs and uses thereof | |
| CN109475592B (zh) | 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物 | |
| US7928058B2 (en) | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition | |
| GROSSMAN | Gastrin and its activities | |
| Beltramo et al. | Rational design of triazololipopeptides analogs of kisspeptin inducing a long-lasting increase of gonadotropins | |
| JP2022509568A (ja) | 修飾されたｇｉｐペプチド類似体 | |
| JP2001527507A (ja) | 改良された環状ｃｒｆ拮抗剤 | |
| US11572399B2 (en) | Long-acting GIP peptide analogues | |
| WO2023207107A1 (zh) | Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途 | |
| KR20250140094A (ko) | Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도 | |
| JPH10510814A (ja) | ベタイドを製造するためのアミノ酸並びにベタイドライブラリーのスクリーニング方法及び製造方法 | |
| CN118843638A (zh) | Crf2受体激动剂及其在治疗中的用途 | |
| CN102076353A (zh) | 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽 | |
| Laimou et al. | Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties | |
| Niida et al. | Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives | |
| JP2004002331A (ja) | 肝臓癌の治療 | |
| WO2023207106A1 (zh) | Glp-1/gip受体共激动剂、包含其的药物组合物及其用途 | |
| EA049082B1 (ru) | Соединения и их применение для лечения нарушений, опосредованных тахикининовым рецептором | |
| Batra et al. | Pneumadin: a new lung peptide which triggers antidiuresis | |
| Guillemette et al. | Angiotensin II: dependence of hormone affinity on the electronegativity of a single side chain | |
| IL322770A (en) | Human transferrin receptor binding peptide |